{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+3&page=79", "query": { "intervention": "Part 3", "page": 79 }, "page_size": 10 }, "pagination": { "page": 79, "page_size": 10, "total_count": 4023, "total_pages": 403, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+3&page=80&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+3&page=78&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-12T15:33:07.298Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04104672", "title": "A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Pancreatic Cancer" ], "interventions": [ { "name": "AB680", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 196, "start_date": "2019-11-06", "completion_date": "2026-07-21", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-11-12T15:33:07.298Z", "location_count": 9, "location_summary": "Santa Monica, California • St Louis, Missouri • New York, New York + 5 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04104672" }, { "nct_id": "NCT06649539", "title": "Delayed Dose Collagenase Clostridium Histolyticum (CCH) Protocol for Men With Peyronie's Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Peyronie Disease" ], "interventions": [ { "name": "Collagenase Clostridium Histolyticum", "type": "DRUG" }, { "name": "RestoreX", "type": "DEVICE" }, { "name": "Sildenafil", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Charitable Union for the Research and Education of Peyronie's Disease", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2024-10-11", "completion_date": "2029-10", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-11-12T15:33:07.298Z", "location_count": 1, "location_summary": "Orem, Utah", "locations": [ { "city": "Orem", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT06649539" }, { "nct_id": "NCT07300475", "title": "Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Triple Negative Breast Cancer" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Personalized cancer vaccine (PCV)", "type": "BIOLOGICAL" }, { "name": "AB248", "type": "DRUG" }, { "name": "pVAC tools neoantigen prediction algorithm", "type": "OTHER" }, { "name": "poly-ICLC", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-12-01", "completion_date": "2035-08-31", "has_results": false, "last_update_posted_date": "2026-11-05", "last_synced_at": "2026-11-12T15:33:07.298Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07300475" }, { "nct_id": "NCT04986202", "title": "Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Heart Failure With Preserved Ejection Fraction" ], "interventions": [ { "name": "AZD4831", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "40 Years to 85 Years" }, "enrollment_count": 711, "start_date": "2021-06-30", "completion_date": "2024-03-27", "has_results": true, "last_update_posted_date": "2025-08-27", "last_synced_at": "2026-11-12T15:33:07.298Z", "location_count": 21, "location_summary": "Alexander City, Alabama • Little Rock, Arkansas • Sacramento, California + 18 more", "locations": [ { "city": "Alexander City", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Sacramento", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04986202" }, { "nct_id": "NCT05615012", "title": "A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "BMS-986322", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Glucose", "type": "DIETARY_SUPPLEMENT" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 76, "start_date": "2022-11-11", "completion_date": "2023-12-13", "has_results": false, "last_update_posted_date": "2024-03-27", "last_synced_at": "2026-11-12T15:33:07.298Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05615012" }, { "nct_id": "NCT03897075", "title": "Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Plaque Psoriasis", "Moderate to Severe Nail Psoriasis" ], "interventions": [ { "name": "Tildrakizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sun Pharmaceutical Industries Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 99, "start_date": "2021-05-13", "completion_date": "2025-01-30", "has_results": true, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-11-12T15:33:07.298Z", "location_count": 11, "location_summary": "Encinitas, California • Fountain Valley, California • Los Angeles, California + 8 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Coral Gables", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03897075" }, { "nct_id": "NCT05979428", "title": "A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers", "Dyslipidaemia" ], "interventions": [ { "name": "NNC0491-6075", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 106, "start_date": "2023-08-07", "completion_date": "2025-03-14", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-11-12T15:33:07.298Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05979428" }, { "nct_id": "NCT02947100", "title": "Omega-3 Fatty Acids in Sickle Cell Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "SCD-Omegatex™", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Robin E. Miller", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "8 Years to 25 Years" }, "enrollment_count": 4, "start_date": "2018-01-25", "completion_date": "2018-10-15", "has_results": true, "last_update_posted_date": "2020-10-19", "last_synced_at": "2026-11-12T15:33:07.298Z", "location_count": 1, "location_summary": "Wilmington, Delaware", "locations": [ { "city": "Wilmington", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT02947100" }, { "nct_id": "NCT07132944", "title": "Development and Feasibility of CTraC-FIT", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Functional Impairment", "Functional Performance" ], "interventions": [ { "name": "CTraC-FIT", "type": "OTHER" }, { "name": "Enhanced Usual Care", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 40, "start_date": "2026-07-01", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-11-12T15:33:07.298Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07132944" }, { "nct_id": "NCT05262400", "title": "A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Solid Tumors" ], "interventions": [ { "name": "PF-07220060 + PF-07104091 combination dose escalation", "type": "DRUG" }, { "name": "PF-07104091 + PF-07220060 + fulvestrant dose expansion", "type": "DRUG" }, { "name": "PF-07104091 + PF-07220060 + letrozole dose expansion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 235, "start_date": "2022-03-14", "completion_date": "2027-02-26", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-11-12T15:33:07.298Z", "location_count": 12, "location_summary": "Los Angeles, California • Santa Monica, California • Boston, Massachusetts + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05262400" } ] }